Literature DB >> 22457516

Food intake in lean and obese mice after peripheral administration of glucagon-like peptide 2.

Sara Baldassano1, Anna Lisa Bellanca, Rosa Serio, Flavia Mulè.   

Abstract

We investigated the potential anorectic action of peripherally administered glucagon-like peptide 2 (GLP2) in lean and diet-induced obese (DIO) mice. Mice, fasted for 16 h, were injected i.p. with native GLP2 or [Gly2]GLP2, stable analog of GLP2, before or after GLP2 (3-33), a GLP2 receptor (GLP2R) antagonist, or exendin (9-39), a GLP1R antagonist. Food intake was measured at intervals 1, 2, 4, 8, and 24 h postinjection. In addition, we tested in lean mice the influence of [Gly2]GLP2 on gastric emptying and the effects of GLP1 alone or in combination with [Gly2]GLP2 on food intake. [Gly2]GLP2 dose dependently and significantly inhibited food intake in lean and DIO mice. The reduction of food intake occurred in the first hour postinjection and it was sustained until 4 h postinjection in lean mice while it was sustained until 2 h postinjection in DIO mice. GLP2 significantly inhibited food intake in both lean and DIO mice but only in the first hour postinjection. The efficiency of [Gly2]GLP2 or GLP2 in suppressing food intake was significantly weaker in DIO mice compared with lean animals. The [Gly2]GLP2 anorectic actions were blocked by the GLP2R antagonist GLP2 (3-33) or by the GLP1R antagonist exendin (9-39). The coadministration of [Gly2]GLP2 and GLP1 did not cause additive effects. [Gly2]GLP2 decreased the gastric emptying rate. Results suggest that GLP2 can reduce food intake in mice in the short term, likely acting at a peripheral level. DIO mice are less sensitive to the anorectic effect of the peptide.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22457516     DOI: 10.1530/JOE-12-0092

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  7 in total

Review 1.  Ghrelin, the proglucagon-derived peptides and peptide YY in nutrient homeostasis.

Authors:  Charlotte X Dong; Patricia L Brubaker
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-10-02       Impact factor: 46.802

2.  Glucagon-like peptide-2 (GLP-2) modulates the cGMP signalling pathway by regulating the expression of the soluble guanylyl cyclase receptor subunits in cultured rat astrocytes.

Authors:  Esther Velázquez; Enrique Blázquez; Juan Miguel Ruiz-Albusac
Journal:  Mol Neurobiol       Date:  2012-07-18       Impact factor: 5.590

3.  The Enteroendocrine System in Obesity.

Authors:  Emily L Miedzybrodzka; Frank Reimann; Fiona M Gribble
Journal:  Handb Exp Pharmacol       Date:  2022

4.  Glucagon-like peptide-2 treatment improves glucose dysmetabolism in mice fed a high-fat diet.

Authors:  Sara Baldassano; Antonella Amato; Gaetano Felice Caldara; Flavia Mulè
Journal:  Endocrine       Date:  2016-01-30       Impact factor: 3.633

Review 5.  Glucagon-related peptides and the regulation of food intake in chickens.

Authors:  Kazuhisa Honda
Journal:  Anim Sci J       Date:  2016-05-06       Impact factor: 1.749

6.  Glucagon-like peptide-2 modulates the nitrergic neurotransmission in strips from the mouse gastric fundus.

Authors:  Rachele Garella; Eglantina Idrizaj; Chiara Traini; Roberta Squecco; Maria Giuliana Vannucchi; Maria Caterina Baccari
Journal:  World J Gastroenterol       Date:  2017-10-28       Impact factor: 5.742

7.  GLP2 Promotes Directed Differentiation from Osteosarcoma Cells to Osteoblasts and Inhibits Growth of Osteosarcoma Cells.

Authors:  Yi Lu; Dongdong Lu; Yu Hu
Journal:  Mol Ther Nucleic Acids       Date:  2017-12-21       Impact factor: 8.886

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.